Eli Lilly partners with AI-focused Genetic Leap to develop RNA-based drugs

U.S. drugmaker Eli Lilly (LLY.N) has signed a research deal with privately held AI-focused firm Genetic Leap to develop genetic medicines, the latter said on Thursday.

Major drugmakers have been experimenting with artificial intelligence to discover new drugs, find patients for clinical trials and reduce the number of people needed to test medicines.